Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Monday, 2 October 2017

Summit Therapeutics to Host R&D Day 11 October 2017

     

Published: 13:00 CEST 02-10-2017 /GlobeNewswire /Source: Summit Therapeutics plc / : SUMM /ISIN: GB00BN40HZ01

Summit Therapeutics to Host R&D Day 11 October 2017

Summit Therapeutics plc

("Summit", or the "Company")

SUMMIT THERAPEUTICS TO HOST R&D DAY 11 OCTOBER 2017 

Oxford, UK, 2 October 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'), will host an R&D Day featuring presentations from experts in quantitative muscle image analysis and CDI alongside Summit's management on 11 October 2017 in New York City. 

This event is open to analysts, institutional investors and members of the press. For more information, email investors@summitplc.com.

A live audio webcast of the presentation will be available through the Investors section on the Company's website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics
Glyn Edwards / Richard Pye (UK office)

Erik Ostrowski / Michelle Avery (US office)

 

 

Tel: +44 (0)1235 443 951

  +1 617 225 4455

Cairn Financial Advisers LLP
(Nominated Adviser)

Liam Murray / Tony Rawlinson

 

 

 

Tel: +44 (0)20 7213 0880

N+1 Singer

(Broker)

Aubrey Powell / Lauren Kettle 

 

 

 

Tel: +44 (0)20 7496 3000

MacDougall Biomedical Communications

(US media contact)

Karen Sharma

 


Tel: +1 781 235 3060
ksharma@macbiocom.com

Consilium Strategic Communications
(Financial public relations, UK)

Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Lindsey Neville


Tel: +44 (0)20 3709 5700

summit@consilium-comms.com

 

-END-





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Summit Therapeutics plc, 85b Park Drive Milton Park, Abingdon OX14 4RY,, United Kingdom
If you would like to unsubscribe and stop receiving these e-mails click here.